Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Connaught TriPedia DTaP vaccine recommended for infants two months and older by FDA cmte..

Executive Summary

CONNAUGHT TRIPEDIA DTaP INFANT USE POSTMARKETING SAFETY STUDIES recommended by FDA's Vaccines & Related Biological Products Advisory Committee Jan. 29 in conjunction with a favorable review of efficacy data. The committee agreed that Phase III efficacy studies and immunogenicity data are adequate to support the conclusion that the vaccine is effective when administered to infants as a primary series at two, four and six months of age.
UsernamePublicRestriction

Register

PS027576

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel